Tisotumab manufacturers
- Tisotumab
-
- $263.00
-
2026-07-28
- CAS:1418628-81-5
- Purity: 99.08% (SEC-HPLC)
- Supply Ability: 10g
|
| | Tisotumab Basic information |
| Product Name: | Tisotumab | | Synonyms: | Tisotumab;Research Grade Tisotumab(DHD00601);Tisotumab (anti-F3);1E10|||1.00E+10;Research Grade Tisotumab | | CAS: | 1418628-81-5 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Tisotumab Structure]() |
| | Tisotumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Tisotumab Usage And Synthesis |
| Uses | Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used for the research of solid tumors[1]. | | in vivo | Tisotumab (DIG-labeled, infused) is delivered to the tumor tissue and then bound to the surface of HPAF-II tumors in HPAF-II tumor bearing mice[2].
| | References | [1] Coleman RL, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 May;22(5):609-619. DOI:10.1016/S1470-2045(21)00056-5
[2] Takao S, et al. Tissue factor targeted near-infrared photoimmunotherapy: a versatile therapeutic approach for malignancies. Cancer Immunol Immunother. 2025 Jan 3;74(2):48. DOI:10.1007/s00262-024-03903-2 |
| | Tisotumab Preparation Products And Raw materials |
|